Analysis tamoxifen, endoxifen, and 4-hydroxytamoxifen in dbs of breast cancer patients by lc-ms/ms

• In: D25 What’s new in industry & science? Part 2 on Thursday, 6 September 2018, 09:10 -09:20
• At: Glasgow (Scotland) (2018)
• Type: Presentation
• By: HARAHAP, Yahdiana (Universitas Indonesia, Indonesia)
• Co-author(s): Yahdiana Harahap
  Baitha Palanggatan Maggadani: Pharmacy, Universitas Indonesia, Depok, Indonesia
  Tesanika Ribka Joulin Sitorus: Pharmacy, Universitas Indonesia, Depok, Indonesia
  Callista Andinie Mulyadi: Pharmacy, Universitas Indonesia, Depok, Indonesia
  Denni Joko Purwanto: Dharmais Cancer Hospital, Dharmais Cancer Hospital, Jakarta, Indonesia
  
• Abstract:

  Background

  The antiestrogen effect of tamoxifen is highly determined by its active metabolites, 4-Hydroxytamoxifen (endoxifen) and 4-Hydroxy-N-Desmethyltamoxifen (4-OHTAM). Monitoring concentration of analyte and metabolites in DBS helps to improve effectiveness of therapy by minimizing drug toxicity and ensuring appropriate dosage regiment with

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login